Correlación entre el volumen molecular tumoral evaluado con PET/TC con  68 Ga-PSMA y los niveles de antígeno prostático específico

Sevastián, S. Medina-Ornelas; Francisco, Oscar; Norma, Y. Hernández-Pedro; Angélica, E. Arellano-Zarate; Blanca, L.

doi:10.1016/j.remn.2017.10.005

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study suggested imaging-derived MTV and simultaneously measured PSA to be correlated, which may support treatment management [25]. In support of the findings reported by other studies, our study established concordance between ∆PSA response and ∆TLP response.…”

Section: Discussionsupporting

confidence: 90%

Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients

Oruç

Güzel

Ebinç

et al. 2021

Nuclear Medicine Communications

View full text Add to dashboard Cite

IntroductionThe present study investigates the role of 68 Ga-PSMA PET/CT-derived whole-body metabolic and volumetric parameters in the prediction of treatment response and prognosis among metastatic hormonerefractory prostate cancer patients undergoing secondgeneration androgen receptor axis-targeted therapy (abiraterone or enzalutamide). Materials and methodsThis retrospective study included 44 metastatic hormone-refractory prostate cancer patients undergoing 68 Ga-PSMA PET/CT, including 29 enzalutamide-treated and 15 abiraterone-treated patients. ResultsOf the 44 patients included in the study, 29 received enzalutamide and 15 received abiraterone. During treatment, the changes in PET parameters were correlated with the PSA (biochemical) response. More specifically, a positive correlation was noted between PSA response and percent change in TLP (∆TLP) response, and there was concordance between the results (r = 0.652, k = 0.42, P < 0.001). Baseline PSA (P =0.05), high MTVw (P = 0.005), the increase in ∆PSA (P = 0.036), ∆TLP (P = 0.039) and percent change in MTV (∆MTV) (P = 0.049) values were identified as factors associated with mortality risk.Multivariate analysis showed that PSA1 [odds ratio (OR): 1.005, 95% confidence interval (CI) 1.002-1.008, P = 0.004], ∆PSA (OR: 14.7, 95% CI 1.50-143.7, P = 0.02) and MTVw1 (OR: 11.4,6, P = 0.04) were independent prognostic factors associated with mortality risk. ConclusionA statistically significant concordance and correlation was noted between 68 Ga-PSMA PET/ CT-derived whole-body metabolic parameters (∆TLP and ∆MTV) and ∆PSA. In addition, the baseline PSA, ∆PSA, ∆TLP, ∆MTV and TMTV were identified as predictive factors for mortality risk.

show abstract

Section: Discussionsupporting

confidence: 90%

Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients

Oruç

Güzel

Ebinç

et al. 2021

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Semi‐quantitative analysis of 68 Ga‐PSMA PET‐CT data showed a significant correlation between serum PSA level at the time of PET‐CT and the total PSMA‐lesion volume per patient. Little data was available in the literature, but Medina‐Ornelas Sevastián et al showed that when serum PSA level at recurrence exceeded 4 ng/mL, the total PSMA‐lesion volume was significantly higher . In addition, we found a significant correlation between PSA at PSMA PET‐CT time and the number of lesions per patient.…”

Section: Discussionsupporting

confidence: 54%

“…Little data was available in the literature, but Medina-Ornelas Sevastián et al showed that when serum PSA level at recurrence exceeded 4 ng/mL, the total PSMA-lesion volume was significantly higher. 16 In addition, we found a significant correlation between PSA at PSMA PET-CT time and the number of lesions per patient. Morigi et al also found this result.…”

Section: Discussionmentioning

confidence: 55%

68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes

et al. 2018

View full text Add to dashboard Cite

Background In this retrospective study, we investigated the impact of 68Ga‐PSMA‐11 PET‐CT (PSMA PET‐CT) upon the treatment plan and therapeutic response obtained for Prostate Cancer (PCa) patients presenting an occult biochemical recurrence. Methods Forty‐two patients with previously negative or doubtful 18F‐Choline (FCH) were enrolled. PET images were recorded 1 h after injection of tracer. Only a few months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results. Results PSMA—positive lesions were detected in 34/42 (80.9%) patients. Detection rates were 85.7% and 89.3% for serum PSA levels lower than 2 ng/mL, and >2 ng/mL, respectively. One hundred seventy‐three lesions were detected: 132/173 in lymph nodes (76.3%), 22/173 as metastatic sites (bone or lung) (12.7%), and 19/173 in the prostate bed (10.9%). As a result of the PSMA PET‐CT, therapeutic management changed in 31/42 patients (73.8%). With a follow‐up of 4.9 ± 2.27 months, 32/42 (76.2%) PSA assays after treatment guided by PSMA PET‐CT were collected. For 37.5% (12/32) of patients, the serum PSA level was lower than 0.2 ng/mL and a PSA decrease of over 50% in 8 (25.0%) other patients were obtained. Conclusion Performing a PSMA PET‐CT when FCH PET‐CT was doubtful or negative allows the recurrence localization in more 80% of patients and this had a major clinical impact, as it resulted in treatment change in more than 70% of patients as well as a significant decrease in PSA levels in more than 60% of them.

show abstract

Valoración de factores predictivos de positividad en PET con 68Ga-PSMA-11 en el cáncer de próstata

Gutierrez-Cardo

Duarte

Garcia-Arguello

et al. 2019

Revista Española de Medicina Nuclear e Imagen Molecular

View full text Add to dashboard Cite

Correlación entre el volumen molecular tumoral evaluado con PET/TC con 68 Ga-PSMA y los niveles de antígeno prostático específico

Cited by 5 publications

References 23 publications

Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients

Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients

68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes

Valoración de factores predictivos de positividad en PET con 68Ga-PSMA-11 en el cáncer de próstata

Contact Info

Product

Resources

About